PT946143E - Composicao gelificada a base de nitro-imidazole. - Google Patents

Composicao gelificada a base de nitro-imidazole.

Info

Publication number
PT946143E
PT946143E PT97950300T PT97950300T PT946143E PT 946143 E PT946143 E PT 946143E PT 97950300 T PT97950300 T PT 97950300T PT 97950300 T PT97950300 T PT 97950300T PT 946143 E PT946143 E PT 946143E
Authority
PT
Portugal
Prior art keywords
imidazole
nitro
composition based
gelified
water
Prior art date
Application number
PT97950300T
Other languages
English (en)
Inventor
Michael Goodman
Lindahl Ake
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10804765&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT946143(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of PT946143E publication Critical patent/PT946143E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT97950300T 1996-12-20 1997-12-19 Composicao gelificada a base de nitro-imidazole. PT946143E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626513.7A GB9626513D0 (en) 1996-12-20 1996-12-20 A pharmaceutical composition

Publications (1)

Publication Number Publication Date
PT946143E true PT946143E (pt) 2006-08-31

Family

ID=10804765

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97950300T PT946143E (pt) 1996-12-20 1997-12-19 Composicao gelificada a base de nitro-imidazole.

Country Status (17)

Country Link
US (1) US6348203B1 (pt)
EP (1) EP0946143B1 (pt)
JP (1) JP2001507018A (pt)
KR (1) KR20000069606A (pt)
AT (1) ATE323466T1 (pt)
AU (1) AU730812B2 (pt)
CA (1) CA2275429A1 (pt)
DE (1) DE69736998T2 (pt)
DK (1) DK0946143T3 (pt)
ES (1) ES2263183T3 (pt)
GB (1) GB9626513D0 (pt)
IE (1) IES970906A2 (pt)
NO (1) NO992980L (pt)
NZ (1) NZ336258A (pt)
PT (1) PT946143E (pt)
WO (1) WO1998027960A2 (pt)
ZA (1) ZA9711455B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
KR100671879B1 (ko) * 1999-07-16 2007-01-19 가부시키가이샤 쇼에이 니트로이미다졸 함유 피부 질환용 외용제
JP2002212073A (ja) * 2001-01-15 2002-07-31 Shoei:Kk 水性液剤
SE0103528D0 (sv) 2001-10-21 2001-10-21 Jan Faergeman Topiska kompositioner med förstärkt effekt
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
SE0301862D0 (sv) * 2003-06-26 2003-06-26 Jan Faergeman Sätt att inhibera tillväxten av mot antibiotika resistenta bakterier
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2866569B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
FR2866570B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee
FR2866568B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
US8258164B2 (en) * 2006-09-12 2012-09-04 Curatek Pharmaceuticals Holding, Inc. Nitroimidazole composition and method
JP5238295B2 (ja) * 2007-03-09 2013-07-17 第一三共ヘルスケア株式会社 低刺激性透明半固形外用剤
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
DE102008006394A1 (de) * 2008-01-28 2009-07-30 Beiersdorf Ag Verwendung von Wirkstoffkomplexen aus Panthenol, Glycerin, Citrat und/oder Bisabolol gegen Pollenallergien
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
WO2012009794A1 (en) * 2010-07-19 2012-01-26 Brusells Ventures Corp. Antimicrobial medical gel composition comprising etherified hydroxyethylcellulose
JP5954928B2 (ja) * 2010-11-19 2016-07-20 大同化成工業株式会社 皮膚潰瘍処置用外用剤のゲル状基剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2840571C (en) 2011-06-28 2020-03-24 Medicis Pharmaceutical Corporation High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
WO2014100569A1 (en) * 2012-12-20 2014-06-26 Medicis Pharmaceutical Corporation High dosage topical metronidazole gel formulations
WO2014210156A1 (en) 2013-06-25 2014-12-31 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
CA3002384C (en) * 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421443C2 (de) * 1984-06-08 1996-09-05 Daicel Chem Stabile Gelmasse und Verfahren zu ihrer Herstellung
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
GB2229443A (en) * 1989-03-07 1990-09-26 American Cyanamid Co Wound dressings
CA2011423A1 (en) * 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
CA1337279C (en) * 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
CA2098913C (en) * 1990-12-21 2002-03-12 Felice Bombart Aqueous vaginal douche and related methods
US5662924A (en) * 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
GB9105995D0 (en) * 1991-03-21 1991-05-08 Smith & Nephew Wound dressing
SE506509C2 (sv) * 1992-04-14 1997-12-22 Bioglan Ab Användning av imidazoler för framställning av en farmaceutisk formulering för behandling av inflammatoriska och/eller infektiösa hudsjukdomar
US5391367A (en) * 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution

Also Published As

Publication number Publication date
IES80590B2 (en) 1998-10-07
NO992980D0 (no) 1999-06-17
CA2275429A1 (en) 1998-07-02
DK0946143T3 (da) 2006-08-21
JP2001507018A (ja) 2001-05-29
NZ336258A (en) 2001-04-27
GB9626513D0 (en) 1997-02-05
AU5330898A (en) 1998-07-17
WO1998027960A3 (en) 1998-09-11
ATE323466T1 (de) 2006-05-15
EP0946143B1 (en) 2006-04-19
DE69736998T2 (de) 2007-03-01
EP0946143A2 (en) 1999-10-06
ES2263183T3 (es) 2006-12-01
NO992980L (no) 1999-08-16
IES970906A2 (en) 1998-10-07
US6348203B1 (en) 2002-02-19
AU730812B2 (en) 2001-03-15
WO1998027960A2 (en) 1998-07-02
ZA9711455B (en) 1998-09-02
DE69736998D1 (de) 2007-01-04
KR20000069606A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
PT946143E (pt) Composicao gelificada a base de nitro-imidazole.
ES2168414T3 (es) Formulaciones de retinoides en microesferas porosas de irritacion reducida y estabilidad aumentada.
NZ295211A (en) Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids
AU2526095A (en) Transdermal device for administration through de-epithelialized skin
EE9800418A (et) Lahustuvad oksiidid bioloogiliseks kasutamiseks
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
GEP20043171B (en) Skin with a Minimal Systemic Effect
ATE274900T1 (de) Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
MA22677A1 (fr) Compositions cosmetiques en gels
GB2007091A (en) Ophthalmic composition
EP0640647A3 (en) Ion-crosslinked glycosaminoglycan gels to increase soft tissue and for drug delivery.
DK0711140T3 (da) Antimykotisk opløsning til negle
BR9501319A (pt) Composição tópica cosmetica e/ou dermatológica utilização desta composição e processo de tratamento cosmético
BR0008787A (pt) Sistema à base de colágeno injetável para aplicação de células ou agentes terapêuticos
DE69824164D1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
BR9903751A (pt) Composição para uso cosmético e/ou dermatológico, utilização cosmética da composição, utilização da composição e utilização de pelo menos um ácido aminossulfÈnico n-substituìdo
ES2182920T3 (es) Formulaciones solubles de 2-cloro02'-deoxiadenosina.
BG103262A (en) Antimycotic gel with high degree of active substance release
SE9403905D0 (sv) New formulations
FR2719475B1 (fr) Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.
AR017170A1 (es) Composicion oftalmologica
ITMI960640A1 (it) Composizioni veterinarie a base di antibatterici per uso intramam- mario
OA09771A (en) Asphodelus composition for increasing white blood cell count.